A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001 in Japanese Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
Price : $35 *
At a glance
- Drugs Formoterol/glycopyrrolate (Primary) ; Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Pearl Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 14 Oct 2014 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.